Big Pharm is flush with cash and has bloodlust for small biotech acquisitions. So where are the buyers for DYAX? DYAX is a diamond in the rough. The life cycle for the current iteration of biologic therapeutics, mainly small proteins and recombinant antibodies, is really just approaching puberty, these agents will be with us for another 10 - 15 years. DYAX has so many partners with products in development (perhaps thats part of the problem ala MEDX) I would think it would be an attractive takeover candidate. Maybe it is in someone's sights, PPS is typically held down (i.e., manipulated) until the potential acquirer has bought all they can without filing. Dont sell now, I think things will turn around dramatically when they do. IMO phage display is an incredibly valuable tool for discovery and development of recombinant protein products, and an approved product is a bonus.